Identifying the best dose of lisinopril to reduce high blood pressure in children who have received a kidney transplant.

This study examined the pharmacokinetics of lisinopril in pediatric kidney transplant recipients. The study enrolled approximately 28 children aged 2-17 years who had stable allograft function and needed medication therapy to control high blood pressure. The study was open to children of both sexes and all racial and ethnic groups. Each child participated in the study for up to 51 days (including 7 days of screening, 14 days of drug administration, and 30 days of safety monitoring).

Uptal Patel, MD, of Duke Clinical Research Institute, discusses the lisinopril in pediatric kidney transplant recipients study.

Summary

Lisinopril is approved by the U.S. Food and Drug Administration for the treatment of high blood pressure (hypertension) in adults and children aged 6+ years. However, the appropriate dose of lisinopril in children below the age of 6 was not well known. In addition, high blood pressure is common among children and adolescents who have received a kidney transplant, but the appropriate dose of lisinopril in this vulnerable group was also unknown.

We administered lisinopril to children and adolescents with high blood pressure who had received a kidney transplant. The levels of lisinopril in each person were measured, thereby allowing the determination of the best dose of lisinopril to reduce high blood pressure in this fragile population.

Publications